Followers | 9841 |
Posts | 260003 |
Boards Moderated | 4 |
Alias Born | 12/27/2006 |
Wednesday, November 11, 2020 5:18:23 PM
Link to Video - click here to watch the technical chart video
Recent EQ News
- Form 8-K - Current report • Edgar (US Regulatory) • 07/23/2024 08:01:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/18/2024 06:08:53 PM
- Equillium Announces Second Quarter 2024 Estimated Cash and Investments Balance • Business Wire • 07/18/2024 05:57:00 PM
- Equillium to Participate in Upcoming Investor Conferences • Business Wire • 07/02/2024 12:00:00 PM
- Equillium to be included in the Russell Microcap® Index • Business Wire • 06/12/2024 12:00:00 PM
- Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 06/05/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 12:00:55 PM
- Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areata • Business Wire • 06/04/2024 12:00:00 PM
- Equillium to Present at the Jefferies Global Healthcare Conference • Business Wire • 05/29/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 09:56:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 09:00:15 PM
- Equillium Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease • Business Wire • 05/14/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:11:09 PM
- Equillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical Highlights • Business Wire • 05/09/2024 08:01:00 PM
- Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists • Business Wire • 05/07/2024 12:00:00 PM
- Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 04/03/2024 12:00:00 PM
- Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis • Business Wire • 04/01/2024 12:00:00 PM
- Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights • Business Wire • 03/25/2024 08:01:00 PM
- Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational Conference • Business Wire • 03/22/2024 12:00:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 10:35:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/08/2024 09:01:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/23/2024 10:12:11 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/23/2024 10:09:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 11:08:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 11:17:47 PM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM